Ingrid Delaet Sells 7,143 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
Ingrid Delaet, an insider at Neurocrine Biosciences, Inc. (NASDAQ:NBIX), sold 7,143 shares on August 13th for approximately $2,072,164.30, leaving her with 2,507 shares valued at around $79,300. This transaction was disclosed in a filing with the SEC. Additionally, shares of NBIX have recently experienced fluctuations, and analysts have mixed opinions, with some maintaining a "Moderate Buy" consensus on the stock with a target price in the range of $55-65.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) insider Ingrid Delaet sold 7,143 shares of the business's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the transaction, the insider now owns 2,507 shares of the company's stock, valued at $376,300.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Get Neurocrine Biosciences alerts:
- Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Ingrid Delaet also recently made the following trade(s):
- On Tuesday, August 6th, Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $147.70, for a total value of $40,322.10.
Neurocrine Biosciences Price Performance
NBIX traded up $1.08 during midday trading on Thursday, reaching $147.77. 720,170 shares of the company's stock traded hands, compared to its average volume of 819,548. The firm has a fifty day moving average of $141.47 and a two-hundred day moving average of $138.88. The stock has a market capitalization of $14.87 billion, a price-to-earnings ratio of 40.55 and a beta of 0.37. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing analysts' consensus estimates of $1.15 by ($0.52). The business had revenue of $590.20 million for the quarter, compared to the consensus estimate of $545.98 million. Neurocrine Biosciences had a net margin of 16.00% and a return on equity of 14.86%. The company's revenue for the quarter was up 30.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.95 EPS. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.22 EPS for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RFP Financial Group LLC grew its stake in shares of Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the last quarter. Mather Group LLC. purchased a new stake in Neurocrine Biosciences during the 1st quarter valued at $26,000. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $28,000. Lindbrook Capital LLC boosted its stake in Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company's stock valued at $28,000 after purchasing an additional 96 shares during the last quarter. Finally, Innealta Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at $30,000. Hedge funds and other institutional investors own 92.59% of the company's stock.
Wall Street Analyst Weigh In
NBIX has been the subject of several recent analyst reports. Oppenheimer boosted their target price on Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. lifted their price target on Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 7th. Wedbush reaffirmed an "outperform" rating and set a $152.00 price target on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Morgan Stanley lifted their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "overweight" rating in a research note on Friday, July 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, July 25th. Six research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.68.
Get Our Latest Research Report on Neurocrine Biosciences
Neurocrine Biosciences Company Profile
(Get Free Report)Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Featured Stories
- Five stocks we like better than Neurocrine Biosciences
- What Are Dividends? Buy the Best Dividend Stocks
- Michael Burry's Alibaba Bet and the Broader Market Implications
- With Risk Tolerance, One Size Does Not Fit All
- Jeff Brown's Exegesis AI Stock Picks
- Find and Profitably Trade Stocks at 52-Week Lows
- Warren Buffett’s Bet: Why Berkshire Hathaway Bought Ulta Stock
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets) (Ad)
Should you invest $1,000 in Neurocrine Biosciences right now?
Before you consider Neurocrine Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neurocrine Biosciences wasn't on the list.
While Neurocrine Biosciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
